State of the ACTG
June, 2017

Daniel R. Kuritzkes, MD
Co-Principal Investigator and Chair
AIDS Clinical Trials Group
Progress on ACTG Trials

- 9 studies completed accrual
  - A5316 (Vaginal Ring & ART PK Study)
  - A5321 (ACTG HIV Reservoirs Cohort-AHRC)
  - A5327 (Sofosbuvir for Acute HCV)
  - A5334s (A5329 PK Substudy)
  - A5346 (Sitagliptin)
  - A5348 (LDV/SOF for HCV Retreatment)
  - A5350 (Effect of Visbiome)
  - A5352s (Epithelial Barrier Substudy of A5350)
  - A5353 (Dolutegravir plus Lamivudine)
Progress on ACTG Trials

12 studies completed follow-up

- A5225 (Fluconazole for Cryptococcal Meningitis)
- A5282 (HPV Test-and-Treat)
- A5308 (ART for HIV Controllers)
- A5314 (Methotrexate)
- A5316 (Vaginal Ring & ART PK Study)
- A5325 (Isotretinoin & CD4 Recovery)
- A5330s (Gut Mucosal Substudy of A5325)
- A5334s (A5329 PK Substudy)
- A5340 (Phase I Study of VRC01 During ATI)
- A5342 (Impact of VRC01 on HIV Persistence)
- A5346 (Sitagliptin)
- A5348 (LDV/SOF for HCV Retreatment)
Progress on ACTG Trials

12 studies completed follow-up
- A5348 (LDV/SOF for HCV Retreatment)
- A5346 (Sitagliptin)
- A5340 (Phase I Study of VRC01 During ATI)
- A5342 (Impact of VRC01 on HIV Persistence)
- A5334s (A5329 PK Substudy)
- A5330s (Gut Mucosal Substudy of A5325)
- A5325 (Isotretinoin & CD4 Recovery)
- A5316 (Vaginal Ring & ART PK Study)
- A5314 (Methotrexate)
- A5308 (ART for HIV Controllers)
- A5282 (HPV Test-and-Treat)
- A5225 (High-dose fluconazole for Crypto Meningitis)
Progress on ACTG Trials

- 5 studies opened to accrual
  - A5343 (Bedaquiline-Delamanid Interaction Study)
  - A5345 (HIV Rebound & Control Biomarkers)
  - A5347s (Reservoir Sampling Substudy of A5345)
  - A5354 (EARLIER)
  - A5361s (PREPARE Substudy of REPRIEVE)
ACTG Accrual (June, 2016– May, 2017)

2,421 enrolled into interventional trials*
  744 enrolled into other observational studies
  474 enrolled into A5128 or A5243

3,649 participants enrolled across all studies

1,722 participants enrolled at international sites
1,924 participants enrolled at US sites
  3 participants enrolled at non-ACTG CRSs

*Includes 1,273 enrolled in Reprieve
ACTG Abstracts and Publications

- 46 abstracts presented at 13 meetings
- 61 manuscripts published or in press in 26 journals
  - AIDS 9
  - Journal of Infectious Diseases 9
  - JAIDS 5
  - Antiviral Therapy 4
  - Clinical Infectious Diseases 4
  - AIDS Res Hum Retrovirol 3
  - Open Forum Infectious Disease 3